Gentiva Health Services Rating Increased to Outperform at Zacks (GTIV)
Gentiva Health Services (NASDAQ:GTIV) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Thursday, Analyst Ratings.Net reports. The firm currently has a $15.00 target price on the stock. Zacks‘ price target suggests a potential upside of 20.87% from the stock’s previous close.
Zacks‘ analyst wrote, “We are upgrading our recommendation on Gentiva to Outperform as we expect the effects of strategic acquisitions and partnerships outweigh the negatives like declining cash flow and shareholder equity, despite the uncertain regulatory environment and legal challenges. Although Gentiva’s third quarter earnings missed the Zacks Consensus Estimate, a raised revenue guidance, on account of the Harden acquisition, and the effect of certain rules related to the U.S. healthcare reform that are awaiting implementation in 2014 raise optimism. Additionally, the focus on specialty services is expected to enhance margins, while the efforts to boost financial flexibility through amendment of credit facility and divestiture of non-core businesses bode well for long-term growth. “
Gentiva Health Services (NASDAQ:GTIV) traded down 2.58% during mid-day trading on Thursday, hitting $12.09. The stock had a trading volume of 96,442 shares. Gentiva Health Services has a one year low of $8.47 and a one year high of $13.85. The stock has a 50-day moving average of $12.27 and a 200-day moving average of $11.61. The company’s market cap is $438.4 million.
Gentiva Health Services (NASDAQ:GTIV) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.08. The company had revenue of $410.50 million for the quarter, compared to the consensus estimate of $417.11 million. During the same quarter in the prior year, the company posted $0.32 earnings per share. The company’s quarterly revenue was down 3.3% on a year-over-year basis.
GTIV has been the subject of a number of other recent research reports. Analysts at Thomson Reuters/Verus upgraded shares of Gentiva Health Services from a “sell” rating to a “hold” rating in a research note to investors on Monday, December 9th. Analysts at Piper Jaffray cut their price target on shares of Gentiva Health Services from $15.00 to $14.00 in a research note to investors on Wednesday, November 6th. They now have an “overweight” rating on the stock. Three research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $13.00.
Gentiva Health Services, Inc (NASDAQ:GTIV) is engaged in providing home health services and hospice services.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.